Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
Company profile
Ticker
CYBN
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
D
$1.90 mm in options, 17 investors
22 Apr 24
6-K
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
18 Apr 24
6-K
Current report (foreign)
18 Apr 24
SUPPL
Supplemental materials (foreign)
18 Apr 24
6-K
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
16 Apr 24
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
10 Apr 24
6-K
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
10 Apr 24
D
$108.70 mm in equity, sold $108.70 mm, 12 investors
3 Apr 24
6-K
Material Change Report
22 Mar 24
6-K
Current report (foreign)
21 Mar 24
Latest ownership filings
SC 13G
RA CAPITAL MANAGEMENT, L.P.
25 Mar 24
SC 13G
Deep Track Capital, LP
22 Mar 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
RANDS PETER DAVID
17 Nov 23
SC 13G
RANDS PETER DAVID
7 Nov 23
SC 13G
Point72 Asset Management, L.P.
15 Sep 23
SC 13G/A
ORBIMED CAPITAL LLC
14 Feb 23
SC 13G
ORBIMED CAPITAL LLC
11 Feb 22
Financial summary
Quarter (USD) | Mar 23 | Mar 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q3 2023
4.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 69 |
Opened positions | 19 |
Closed positions | 10 |
Increased positions | 10 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 24.41 bn |
Total shares | 29.57 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Point72 Asset Management | 18.95 mm | $10.07 bn |
Orbimed Capital | 6.15 mm | $0.00 |
AdvisorShares Investments | 1.95 mm | $1.04 bn |
Simplify Asset Management | 500.00 k | $265.70 mm |
Jane Street | 374.85 k | $197.51 mm |
VIRT Virtu Financial | 135.59 k | $72.15 mm |
IAG Wealth Partners | 99.94 k | $53.11 mm |
Formidable Asset Management | 86.35 k | $45.89 mm |
Wedbush Securities | 66.50 k | $35.00 k |
Powell Investment Advisors | 60.00 k | $31.88 mm |
News
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
30 Mar 24
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
20 Mar 24
Reported Earlier, 'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana Moment
14 Mar 24
Cybin Announces End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
14 Mar 24
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
13 Mar 24
Press releases
Cybin to Participate at the 27th Annual Milken Institute Global Conference
25 Apr 24
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
18 Apr 24
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
16 Apr 24
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
10 Apr 24
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
18 Mar 24